Suppr超能文献

质子束治疗继发性胶质母细胞瘤患者(髓母细胞瘤术后放疗 32 年后):病例报告及文献复习。

Proton beam therapy in a patient with secondary glioblastoma (32 years after postoperative irradiation of medulloblastoma): case report and literature review.

机构信息

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.

Department of Radiation Oncology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, 305-8575, Japan.

出版信息

Radiat Oncol. 2024 Oct 5;19(1):136. doi: 10.1186/s13014-024-02515-5.

Abstract

OBJECTIVE

This report details the experience of a patient who developed a second primary glioblastoma (GB), offering insights into the treatment process and reviewing relevant literature.

CASE PRESENTATION

A male patient, who was diagnosed with medulloblastoma at age 9, received treatment with cobalt-60 craniospinal irradiation (CSI) (36 Gy/20 fractions) and a tumor bed boost (total of 56 Gy). After 32 years, at age 41, an MRI revealed a space-occupying mass in the left cerebellar hemisphere. Surgical resection was performed, and postoperative pathology confirmed a diagnosis of radiation-induced glioblastoma (RIGB). Given the history of irradiation and the current tolerability of brainstem doses, proton beam therapy (PBT) combined with Temozolomide (75 mg/m) was chosen. The treatment plan included 60 Gy on the gross tumor bed and 54 Gy on the clinical target volume, delivered in 30 fractions. The patient underwent regular follow-up and achieved a complete response.

CLINICAL DISCUSSION

For childhood cancer survivors, the development of a second primary tumor significantly impacts prognosis. RIGB is a rare form of secondary tumor with distinct molecular characteristics compared to primary GB and recurrent secondary GB. Molecular markers such as IDH and MGMT status can help differentiate between primary GB, recurrent secondary GB, and radiation-induced secondary GB in patients with a history of prior radiation therapy. Surgical resection remains a primary treatment option, while PBT is preferred for postoperative treatment due to its superior protection of normal tissues and the ability to deliver high-dose irradiation.

CONCLUSION

RIGB is a rare second primary tumor that requires strategic molecular profiling and individualized management. Proton beam therapy provides effective high-dose irradiation in the postoperative phase and is the preferred treatment option for such cases.

摘要

目的

本报告详细介绍了一名患者发生第二原发胶质母细胞瘤(GB)的经历,为治疗过程提供了深入了解,并回顾了相关文献。

病例介绍

一名男性患者,9 岁时被诊断患有髓母细胞瘤,接受了钴-60 颅脊髓照射(CSI)(36Gy/20 次)和肿瘤床加量(总剂量 56Gy)治疗。32 年后,41 岁时,MRI 显示左小脑半球有占位性病变。进行了手术切除,术后病理证实为放射性诱导的胶质母细胞瘤(RIGB)。鉴于放疗史和目前脑干剂量的耐受性,选择了质子束治疗(PBT)联合替莫唑胺(75mg/m)。治疗计划包括在大体肿瘤床给予 60Gy 和在临床靶区给予 54Gy,共 30 次。患者接受了定期随访,并获得了完全缓解。

临床讨论

对于儿童癌症幸存者,第二原发肿瘤的发生显著影响预后。RIGB 是一种罕见的继发性肿瘤,与原发性 GB 和复发性继发性 GB 相比具有独特的分子特征。IDH 和 MGMT 状态等分子标志物有助于区分有放疗史的患者中的原发性 GB、复发性继发性 GB 和放射性诱导的继发性 GB。手术切除仍然是主要的治疗选择,而 PBT 是术后治疗的首选,因为它能更好地保护正常组织,并能给予高剂量照射。

结论

RIGB 是一种罕见的第二原发肿瘤,需要进行策略性的分子分析和个体化管理。质子束治疗在术后阶段提供有效的高剂量照射,是此类病例的首选治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3817/11453085/97ce0fdbb499/13014_2024_2515_Figa_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验